The Indian pharmaceutical industry, known as the ‘pharmacy of the world’, has faced a trend of negative net voluntary licensing and technology transfers – constructive for medicine access in LMICs, according to the 2024 Access to Medicine Index. Rele
Marksans Pharma Limited has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. These tablets are intended for over-the-counter (OTC) use to tre...
The rapid advancements in quality control techniques and testing methods have been driven by the rising need for safe, effective medications of high quality. The market is growing due to increased attention on product quality and adherence to...
The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 brought together over 290 professionals from leading pharmaceutical companies such as Roche, Johnson&Johnson, Moderna, Pfizer, Novartis, Takeda and other key players.
Elon Musk’s Neuralink announced on Wednesday that it has received approval to initiate its first clinical trial in Canada, focusing on a device designed to enable individuals with paralysis to control digital devices using their thoughts. The stud...
Long-term health management products, specifically chronic therapies, have been driving the growth of the Indian Pharmaceutical Market (IPM) with a 10% increase, in contrast to acute therapies which saw a 2% growth, showing a trend towards prolong...
The MHRA in the UK has given the approval to sparsentan (Filspari) for the treatment of IgAN. Berger's disease, or IgA neuropathy, is a kidney condition caused by the accumulation of immunoglobulin A (IgA) antibodies in the kidneys. Sparsentan...
Anti-diabetics and cardiac treatments are the main drivers of the domestic pharmaceutical market, with respiratory treatments projected to be the primary growth drivers in November, December, and January. With air pollution persisting, it is...
Glenmark became the first Indian company to introduce a biosimilar of the anti-diabetic GLP-1 drug Liraglutide in India. Additionally, it has revealed a number of collaborations to introduce new drugs, such as partnerships with Jiangsu Alphamab...
The exclusive license agreement permits Pharmanovia to launch catumaxomab, a unique trifunctional bi-specific monoclonal antibody, for intraperitoneal treatment of malignant ascites in EpCAM-positive carcinoma patients ineligible for additional...
, CDSCO.jpg)
